...
首页> 外文期刊>Forensic toxicology >Development and validation of a liquid chromatography-mass spectrometry procedure after solid-phase extraction for detection of 19 doping peptides in human urine
【24h】

Development and validation of a liquid chromatography-mass spectrometry procedure after solid-phase extraction for detection of 19 doping peptides in human urine

机译:固相萃取后液相色谱-质谱法检测人尿中19种掺杂肽的开发和验证

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A liquid chromatography-tandem mass spectrometry method was developed and used to simultaneously detect 19 small peptide hormones prohibited in sport and their main metabolites in urine after solid-phase extraction. Detection was achieved using a triple-quadrupole mass spectrometric detector coupled with an electrospray ionization interface after chromatographic separation with an octadecyl column based on fused-core particle technology. Sample pretreatment was performed by solid-phase extraction. The extraction procedure was optimized by comparison of different sorbents and washing/elution protocols. The best results were obtained using a mixed-mode weak cation exchange sorbent, two washing steps (ultrapurified water and methanol), and elution using 300 mM ammonium formate in 25 % ammonia/methanol (10/90) or 25 % ammonia/10 % formic acid/methanol (8/12/80). The procedure was validated in terms of sensitivity (lower limits of detection: 0.05-2.0 ng/ml depending on the target analyte), specificity, recovery [> 60 %, coefficient of variation (CV) < 15 % except for TB500 17-23 fragment, AOD9604, and ARA290 for which recovery was < 50 %), ion suppression/enhancement (< 35 %), robustness, carryover, stability of the target analytes [stable for at least for 2 days (25 A degrees C, 2 weeks (4 A degrees C), 2 months (-20 A degrees C)], and repeatability of retention times (CV < 0.1 %) and relative abundances of the selected ion transitions (CV < 15 %). The suitability of the method was confirmed by analyzing spiked and excreted urines, the latter collected after intravenous injection of 0.1 mg of GHRP-2.
机译:开发了一种液相色谱-串联质谱法,用于固相萃取后同时检测运动中禁止的19种小肽激素及其在尿液中的主要代谢产物。在基于熔融核粒子技术的十八烷基柱色谱分离后,使用三重四极杆质谱检测器结合电喷雾电离界面实现检测。样品预处理通过固相萃取进行。通过比较不同的吸附剂和洗涤/洗脱方案,优化了提取程序。使用混合模式弱阳离子交换吸附剂,两个洗涤步骤(超纯水和甲醇),以及在25%氨/甲醇(10/90)或25%氨/ 10%中的300 mM甲酸铵洗脱,可获得最佳结果。甲酸/甲醇(8/12/80)。该程序在灵敏度(检测下限:0.05-2.0 ng / ml,取决于目标分析物),特异性,回收率[> 60%,变异系数(CV)<15%(TB500 17-23除外)方面得到验证回收率小于50%的片段,AOD9604和ARA290,离子抑制/增强(<35%),稳健性,残留,目标分析物的稳定性[稳定至少2天(25 A摄氏度,2周) (4 A摄氏度,2个月(-20 A摄氏度)],保留时间的重复性(CV <0.1%)和所选离子跃迁的相对丰度(CV <15%)。通过分析加标和排泄的尿液来确定尿液,静脉注射0.1 mg GHRP-2后收集尿液。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号